Cancer

Molecular therapy for glioblastoma: A therapeutic mix encompassing Macbecin, Temozolomide, EGCG, Salinomycin, Fluvastatin and Chloroquine (MTESF) inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 4/February/2018, 11.57 pm
Molecular therapy for glioblastoma: A therapeutic mix encompassing Macbecin, Temozolomide, EGCG, Salinomycin, Fluvastatin and Chloroquine (MTESF) inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 4/February/2018, 11.57 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors represent in vivo cancer…

read more

Molecular therapy for CyclinD3-CDK6 overexpressing cancers: Roscovitine, a cyclin kinase-dependent inhibitor,  inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 4/February/2018, 11.32pm
Molecular therapy for CyclinD3-CDK6 overexpressing cancers: Roscovitine, a cyclin kinase-dependent inhibitor,  inhibits the activity of glycolytic enzymes 6-phosphofructokinase and pyruvate kinase M2, decreases antioxidants NADPH and glutathione levels, increases reactive oxygen species levels, promotes apoptosis, and inhibits the progression of CyclinD3-CDK6 overexpressing cancers via down regulation of its target gene, 4/February/2018, 11.32pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; and Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA shows that “The…

read more

Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor suppressors CADM1 and RECK1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 25/January/2018, 12.03 am
Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor suppressors CADM1 and RECK1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 25/January/2018, 12.03 am 960 720 Dr Boomi's Genom-2-Discovery Center

From significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor/metastatic suppressors TIMP3 and CCM3/KRIT1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/January/2018, 10.51 pm
Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor/metastatic suppressors TIMP3 and CCM3/KRIT1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/January/2018, 10.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor/metastatic suppressors TPM1 and TAp63, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 20/January/2018, 10.47 pm
Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor/metastatic suppressors TPM1 and TAp63, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 20/January/2018, 10.47 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Panaxynol, Procainamide, Pitavastatin,  Protriptyline, Salinomycin  And Temozolomide (PPPPSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/January/2018, 9.14 am
Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Panaxynol, Procainamide, Pitavastatin,  Protriptyline, Salinomycin  And Temozolomide (PPPPSAT) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signalling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 16/January/2018, 9.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, David Geffen UCLA…

read more
Start Typing